

# ICD-10 Procedure Coding System (ICD-10-PCS) 2024 Tables Addenda

ICD-10-PCS Tables that have changed this year are shown in table format in the pages below. Click on a bookmark to go to a specific table.

Each table shown in the addenda replaces the table from the previous year.

# 02H

No change	<b>Section</b> <b>0</b> Medical and Surgical <b>Body System</b> <b>2</b> Heart and Great Vessels <b>Operation</b> <b>H</b> Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part			
Heading	<b>Body Part</b> <b>Approach</b> <b>Device</b> <b>Qualifier</b>			
No change	<b>0</b> Coronary Artery, One Artery <b>1</b> Coronary Artery, Two Arteries <b>2</b> Coronary Artery, Three Arteries <b>3</b> Coronary Artery, Four or More Arteries	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>D</b> Intraluminal Device <b>Y</b> Other Device	<b>Z</b> No Qualifier
No change	<b>4</b> Coronary Vein <b>6</b> Atrium, Right <b>7</b> Atrium, Left <b>K</b> Ventricle, Right <b>L</b> Ventricle, Left	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>0</b> Monitoring Device, Pressure Sensor <b>2</b> Monitoring Device <b>3</b> Infusion Device <b>D</b> Intraluminal Device <b>J</b> Cardiac Lead, Pacemaker <b>K</b> Cardiac Lead, Defibrillator <b>M</b> Cardiac Lead <b>N</b> Intracardiac Pacemaker <b>Y</b> Other Device	<b>Z</b> No Qualifier
No change	<b>A</b> Heart	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>Q</b> Implantable Heart Assist System <b>Y</b> Other Device	<b>Z</b> No Qualifier
No change	<b>A</b> Heart	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>R</b> Short-term External Heart Assist System	<b>J</b> Intraoperative <b>S</b> Biventricular <b>Z</b> No Qualifier
No change	<b>N</b> Pericardium	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>0</b> Monitoring Device, Pressure Sensor <b>2</b> Monitoring Device <b>J</b> Cardiac Lead, Pacemaker <b>K</b> Cardiac Lead, Defibrillator <b>M</b> Cardiac Lead <b>Y</b> Other Device	<b>Z</b> No Qualifier
FY2024	<b>P</b> Pulmonary Trunk <b>Q</b> Pulmonary Artery, Right <b>R</b> Pulmonary Artery, Left <b>S</b> Pulmonary Vein, Right <b>T</b> Pulmonary Vein, Left <b>V</b> Superior Vena Cava	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>0</b> Monitoring Device, Pressure Sensor <b>2</b> Monitoring Device <b>3</b> Infusion Device <b>D</b> Intraluminal Device <b>Y</b> Other Device	<b>Z</b> No Qualifier
FY2024	<b>W</b> Thoracic Aorta, Descending	<b>0</b> Open <b>4</b> Percutaneous Endoscopic	<b>0</b> Monitoring Device, Pressure Sensor <b>2</b> Monitoring Device <b>3</b> Infusion Device <b>D</b> Intraluminal Device <b>Y</b> Other Device	<b>Z</b> No Qualifier
FY2024	<b>W</b> Thoracic Aorta, Descending	<b>3</b> Percutaneous	<b>0</b> Monitoring Device, Pressure Sensor <b>2</b> Monitoring Device <b>3</b> Infusion Device <b>D</b> Intraluminal Device <b>R</b> Short-term External Heart Assist System <b>Y</b> Other Device	<b>Z</b> No Qualifier

No change

<b>X</b> Thoracic Aorta, Ascending/Arch	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>0</b> Monitoring Device, Pressure Sensor <b>2</b> Monitoring Device <b>3</b> Infusion Device <b>D</b> Intraluminal Device	<b>Z</b> No Qualifier
--	---	--	-----------------------

# 02P

No change	<b>Section</b> <b>0</b> Medical and Surgical <b>Body System</b> <b>2</b> Heart and Great Vessels <b>Operation</b> <b>P</b> Removal: Taking out or off a device from a body part			
Heading	<b>Body Part</b>	<b>Approach</b>	<b>Device</b>	<b>Qualifier</b>
No change	<b>A</b> Heart	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>2</b> Monitoring Device <b>3</b> Infusion Device <b>7</b> Autologous Tissue Substitute <b>8</b> Zooplastic Tissue <b>C</b> Extraluminal Device <b>D</b> Intraluminal Device <b>J</b> Synthetic Substitute <b>K</b> Nonautologous Tissue Substitute <b>M</b> Cardiac Lead <b>N</b> Intracardiac Pacemaker <b>Q</b> Implantable Heart Assist System <b>Y</b> Other Device	<b>Z</b> No Qualifier
No change	<b>A</b> Heart	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>R</b> Short-term External Heart Assist System	<b>S</b> Biventricular <b>Z</b> No Qualifier
No change	<b>A</b> Heart	<b>X</b> External	<b>2</b> Monitoring Device <b>3</b> Infusion Device <b>D</b> Intraluminal Device <b>M</b> Cardiac Lead	<b>Z</b> No Qualifier
FY2024	<b>W</b> Thoracic Aorta, Descending	<b>3</b> Percutaneous	<b>R</b> Short-term External Heart Assist System	<b>Z</b> No Qualifier
No change	<b>Y</b> Great Vessel	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>2</b> Monitoring Device <b>3</b> Infusion Device <b>7</b> Autologous Tissue Substitute <b>8</b> Zooplastic Tissue <b>C</b> Extraluminal Device <b>D</b> Intraluminal Device <b>J</b> Synthetic Substitute <b>K</b> Nonautologous Tissue Substitute <b>Y</b> Other Device	<b>Z</b> No Qualifier
No change	<b>Y</b> Great Vessel	<b>X</b> External	<b>2</b> Monitoring Device <b>3</b> Infusion Device <b>D</b> Intraluminal Device	<b>Z</b> No Qualifier

# 02W

No change	<p><i>Section</i>           <b>0</b> Medical and Surgical</p> <p><i>Body System</i>       <b>2</b> Heart and Great Vessels</p> <p><i>Operation</i>           <b>W</b> Revision: Correcting, to the extent possible, a portion of a malfunctioning device or the position of a displaced device</p>			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>
No change	<b>5</b> Atrial Septum <b>M</b> Ventricular Septum	<b>0</b> Open <b>4</b> Percutaneous Endoscopic	<b>J</b> Synthetic Substitute	<b>Z</b> No Qualifier
No change	<b>A</b> Heart	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>2</b> Monitoring Device <b>3</b> Infusion Device <b>7</b> Autologous Tissue Substitute <b>8</b> Zooplasic Tissue <b>C</b> Extraluminal Device <b>D</b> Intraluminal Device <b>J</b> Synthetic Substitute <b>K</b> Nonautologous Tissue Substitute <b>M</b> Cardiac Lead <b>N</b> Intracardiac Pacemaker <b>Q</b> Implantable Heart Assist System <b>Y</b> Other Device	<b>Z</b> No Qualifier
No change	<b>A</b> Heart	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>R</b> Short-term External Heart Assist System	<b>S</b> Biventricular <b>Z</b> No Qualifier
No change	<b>A</b> Heart	<b>X</b> External	<b>2</b> Monitoring Device <b>3</b> Infusion Device <b>7</b> Autologous Tissue Substitute <b>8</b> Zooplasic Tissue <b>C</b> Extraluminal Device <b>D</b> Intraluminal Device <b>J</b> Synthetic Substitute <b>K</b> Nonautologous Tissue Substitute <b>M</b> Cardiac Lead <b>N</b> Intracardiac Pacemaker <b>Q</b> Implantable Heart Assist System	<b>Z</b> No Qualifier
No change	<b>A</b> Heart	<b>X</b> External	<b>R</b> Short-term External Heart Assist System	<b>S</b> Biventricular <b>Z</b> No Qualifier
No change	<b>F</b> Aortic Valve <b>G</b> Mitral Valve <b>H</b> Pulmonary Valve <b>J</b> Tricuspid Valve	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>7</b> Autologous Tissue Substitute <b>8</b> Zooplasic Tissue <b>J</b> Synthetic Substitute <b>K</b> Nonautologous Tissue Substitute	<b>Z</b> No Qualifier
FY2024	<b>W</b> Thoracic Aorta, Descending	<b>3</b> Percutaneous	<b>R</b> Short-term External Heart Assist System	<b>Z</b> No Qualifier

No change	<b>Y</b> Great Vessel	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>2</b> Monitoring Device <b>3</b> Infusion Device <b>7</b> Autologous Tissue Substitute <b>8</b> Zooplastic Tissue <b>C</b> Extraluminal Device <b>D</b> Intraluminal Device <b>J</b> Synthetic Substitute <b>K</b> Nonautologous Tissue Substitute <b>Y</b> Other Device	<b>Z</b> No Qualifier
No change	<b>Y</b> Great Vessel	<b>X</b> External	<b>2</b> Monitoring Device <b>3</b> Infusion Device <b>7</b> Autologous Tissue Substitute <b>8</b> Zooplastic Tissue <b>C</b> Extraluminal Device <b>D</b> Intraluminal Device <b>J</b> Synthetic Substitute <b>K</b> Nonautologous Tissue Substitute	<b>Z</b> No Qualifier

# OCS

No change	<i>Section</i>	<b>0</b> Medical and Surgical		
	<i>Body System</i>	<b>C</b> Mouth and Throat		
	<i>Operation</i>	<b>S</b> Reposition: Moving to its normal location, or other suitable location, all or a portion of a body part		
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>
No change	<b>0</b> Upper Lip <b>1</b> Lower Lip <b>2</b> Hard Palate <b>3</b> Soft Palate <b>7</b> Tongue <b>N</b> Uvula	<b>0</b> Open <b>X</b> External	<b>Z</b> No Device	<b>Z</b> No Qualifier
No change	<b>B</b> Parotid Duct, Right <b>C</b> Parotid Duct, Left	<b>0</b> Open <b>3</b> Percutaneous	<b>Z</b> No Device	<b>Z</b> No Qualifier
FY2024	<b>R</b> Epiglottis <b>S</b> Larynx <b>T</b> Vocal Cord, Right <b>V</b> Vocal Cord, Left	<b>0</b> Open <b>7</b> Via Natural or Artificial Opening <b>8</b> Via Natural or Artificial Opening Endoscopic	<b>Z</b> No Device	<b>Z</b> No Qualifier
No change	<b>W</b> Upper Tooth <b>X</b> Lower Tooth	<b>0</b> Open <b>X</b> External	<b>5</b> External Fixation Device <b>Z</b> No Device	<b>0</b> Single <b>1</b> Multiple <b>2</b> All

# ODH

No change	<b>Section</b> <b>0</b> Medical and Surgical <b>Body System</b> <b>D</b> Gastrointestinal System <b>Operation</b> <b>H</b> Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part
Heading	<b>Body Part</b> <b>Approach</b> <b>Device</b> <b>Qualifier</b>
No change	<b>0</b> Upper Intestinal Tract <b>D</b> Lower Intestinal Tract  <b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic <b>7</b> Via Natural or Artificial Opening <b>8</b> Via Natural or Artificial Opening Endoscopic
FY2024	<b>1</b> Esophagus, Upper <b>2</b> Esophagus, Middle <b>3</b> Esophagus, Lower  <b>7</b> Via Natural or Artificial Opening  <b>J</b> Magnetic Lengthening Device  <b>Z</b> No Qualifier
No change	<b>5</b> Esophagus  <b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic  <b>1</b> Radioactive Element <b>2</b> Monitoring Device <b>3</b> Infusion Device <b>D</b> Intraluminal Device <b>U</b> Feeding Device <b>Y</b> Other Device  <b>Z</b> No Qualifier
No change	<b>5</b> Esophagus  <b>7</b> Via Natural or Artificial Opening <b>8</b> Via Natural or Artificial Opening Endoscopic  <b>1</b> Radioactive Element <b>2</b> Monitoring Device <b>3</b> Infusion Device <b>B</b> Intraluminal Device, Airway <b>D</b> Intraluminal Device <b>U</b> Feeding Device <b>Y</b> Other Device  <b>Z</b> No Qualifier
No change	<b>6</b> Stomach  <b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic  <b>1</b> Radioactive Element <b>2</b> Monitoring Device <b>3</b> Infusion Device <b>D</b> Intraluminal Device <b>M</b> Stimulator Lead <b>U</b> Feeding Device <b>Y</b> Other Device  <b>Z</b> No Qualifier
No change	<b>6</b> Stomach  <b>7</b> Via Natural or Artificial Opening <b>8</b> Via Natural or Artificial Opening Endoscopic  <b>1</b> Radioactive Element <b>2</b> Monitoring Device <b>3</b> Infusion Device <b>D</b> Intraluminal Device <b>U</b> Feeding Device <b>Y</b> Other Device  <b>Z</b> No Qualifier
No change	<b>8</b> Small Intestine <b>9</b> Duodenum <b>A</b> Jejunum <b>B</b> Ileum  <b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic <b>7</b> Via Natural or Artificial Opening <b>8</b> Via Natural or Artificial Opening Endoscopic  <b>1</b> Radioactive Element <b>2</b> Monitoring Device <b>3</b> Infusion Device <b>D</b> Intraluminal Device <b>U</b> Feeding Device  <b>Z</b> No Qualifier



No change	<b>E</b> Large Intestine <b>P</b> Rectum	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic <b>7</b> Via Natural or Artificial Opening <b>8</b> Via Natural or Artificial Opening Endoscopic	<b>1</b> Radioactive Element <b>D</b> Intraluminal Device	<b>Z</b> No Qualifier
No change	<b>Q</b> Anus	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>D</b> Intraluminal Device <b>L</b> Artificial Sphincter	<b>Z</b> No Qualifier
No change	<b>Q</b> Anus	<b>7</b> Via Natural or Artificial Opening <b>8</b> Via Natural or Artificial Opening Endoscopic	<b>D</b> Intraluminal Device	<b>Z</b> No Qualifier
No change	<b>R</b> Anal Sphincter	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>M</b> Stimulator Lead	<b>Z</b> No Qualifier

# OWH

No change	<b>Section</b> <b>0</b> Medical and Surgical <b>Body System</b> <b>W</b> Anatomical Regions, General <b>Operation</b> <b>H</b> Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part			
Heading FY2024	<b>Body Part</b>	<b>Approach</b>	<b>Device</b>	<b>Qualifier</b>
	<b>0</b> Head <b>1</b> Cranial Cavity <b>2</b> Face <b>3</b> Oral Cavity and Throat <b>4</b> Upper Jaw <b>5</b> Lower Jaw <b>6</b> Neck <b>8</b> Chest Wall <b>9</b> Pleural Cavity, Right <b>B</b> Pleural Cavity, Left <b>D</b> Pericardial Cavity <b>F</b> Abdominal Wall <b>G</b> Peritoneal Cavity <b>H</b> Retroperitoneum <b>J</b> Pelvic Cavity <b>K</b> Upper Back <b>L</b> Lower Back <b>M</b> Perineum, Male <b>N</b> Perineum, Female	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>1</b> Radioactive Element <b>3</b> Infusion Device <b>Y</b> Other Device	<b>Z</b> No Qualifier
FY2024	<b>C</b> Mediastinum	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>1</b> Radioactive Element <b>3</b> Infusion Device <b>G</b> Defibrillator Lead <b>Y</b> Other Device	<b>Z</b> No Qualifier
No change	<b>P</b> Gastrointestinal Tract <b>Q</b> Respiratory Tract <b>R</b> Genitourinary Tract	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic <b>7</b> Via Natural or Artificial Opening <b>8</b> Via Natural or Artificial Opening Endoscopic	<b>1</b> Radioactive Element <b>3</b> Infusion Device <b>Y</b> Other Device	<b>Z</b> No Qualifier

# OWP

No change	<i>Section</i>	<b>0</b> Medical and Surgical		
	<i>Body System</i>	<b>W</b> Anatomical Regions, General		
	<i>Operation</i>	<b>P</b> Removal: Taking out or off a device from a body part		
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>
FY2024	<b>0</b> Head <b>2</b> Face <b>4</b> Upper Jaw <b>5</b> Lower Jaw <b>6</b> Neck <b>8</b> Chest Wall <b>F</b> Abdominal Wall <b>K</b> Upper Back <b>L</b> Lower Back <b>M</b> Perineum, Male <b>N</b> Perineum, Female	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic <b>X</b> External	<b>0</b> Drainage Device <b>1</b> Radioactive Element <b>3</b> Infusion Device <b>7</b> Autologous Tissue Substitute <b>J</b> Synthetic Substitute <b>K</b> Nonautologous Tissue Substitute <b>Y</b> Other Device	<b>Z</b> No Qualifier
No change	<b>1</b> Cranial Cavity <b>9</b> Pleural Cavity, Right <b>B</b> Pleural Cavity, Left <b>G</b> Peritoneal Cavity <b>J</b> Pelvic Cavity	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>0</b> Drainage Device <b>1</b> Radioactive Element <b>3</b> Infusion Device <b>J</b> Synthetic Substitute <b>Y</b> Other Device	<b>Z</b> No Qualifier
No change	<b>1</b> Cranial Cavity <b>9</b> Pleural Cavity, Right <b>B</b> Pleural Cavity, Left <b>G</b> Peritoneal Cavity <b>J</b> Pelvic Cavity	<b>X</b> External	<b>0</b> Drainage Device <b>1</b> Radioactive Element <b>3</b> Infusion Device	<b>Z</b> No Qualifier
FY2024	<b>C</b> Mediastinum	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic <b>X</b> External	<b>0</b> Drainage Device <b>1</b> Radioactive Element <b>3</b> Infusion Device <b>7</b> Autologous Tissue Substitute <b>G</b> Defibrillator Lead <b>J</b> Synthetic Substitute <b>K</b> Nonautologous Tissue Substitute <b>Y</b> Other Device	<b>Z</b> No Qualifier
No change	<b>D</b> Pericardial Cavity <b>H</b> Retroperitoneum	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>0</b> Drainage Device <b>1</b> Radioactive Element <b>3</b> Infusion Device <b>Y</b> Other Device	<b>Z</b> No Qualifier
No change	<b>D</b> Pericardial Cavity <b>H</b> Retroperitoneum	<b>X</b> External	<b>0</b> Drainage Device <b>1</b> Radioactive Element <b>3</b> Infusion Device	<b>Z</b> No Qualifier
No change	<b>P</b> Gastrointestinal Tract <b>Q</b> Respiratory Tract <b>R</b> Genitourinary Tract	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic <b>7</b> Via Natural or Artificial Opening <b>8</b> Via Natural or Artificial Opening Endoscopic <b>X</b> External	<b>1</b> Radioactive Element <b>3</b> Infusion Device <b>Y</b> Other Device	<b>Z</b> No Qualifier

# OWW

No change	<i>Section</i>	<b>0</b> Medical and Surgical		
	<i>Body System</i>	<b>W</b> Anatomical Regions, General		
	<i>Operation</i>	<b>W</b> Revision: Correcting, to the extent possible, a portion of a malfunctioning device or the position of a displaced device		
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>
FY2024	<b>0</b> Head <b>2</b> Face <b>4</b> Upper Jaw <b>5</b> Lower Jaw <b>6</b> Neck <b>8</b> Chest Wall <b>F</b> Abdominal Wall <b>K</b> Upper Back <b>L</b> Lower Back <b>M</b> Perineum, Male <b>N</b> Perineum, Female	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic <b>X</b> External	<b>0</b> Drainage Device <b>1</b> Radioactive Element <b>3</b> Infusion Device <b>7</b> Autologous Tissue Substitute <b>J</b> Synthetic Substitute <b>K</b> Nonautologous Tissue Substitute <b>Y</b> Other Device	<b>Z</b> No Qualifier
No change	<b>1</b> Cranial Cavity <b>9</b> Pleural Cavity, Right <b>B</b> Pleural Cavity, Left <b>G</b> Peritoneal Cavity <b>J</b> Pelvic Cavity	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic <b>X</b> External	<b>0</b> Drainage Device <b>1</b> Radioactive Element <b>3</b> Infusion Device <b>J</b> Synthetic Substitute <b>Y</b> Other Device	<b>Z</b> No Qualifier
FY2024	<b>C</b> Mediastinum	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic <b>X</b> External	<b>0</b> Drainage Device <b>1</b> Radioactive Element <b>3</b> Infusion Device <b>7</b> Autologous Tissue Substitute <b>G</b> Defibrillator Lead <b>J</b> Synthetic Substitute <b>K</b> Nonautologous Tissue Substitute <b>Y</b> Other Device	<b>Z</b> No Qualifier
No change	<b>D</b> Pericardial Cavity <b>H</b> Retroperitoneum	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic <b>X</b> External	<b>0</b> Drainage Device <b>1</b> Radioactive Element <b>3</b> Infusion Device <b>Y</b> Other Device	<b>Z</b> No Qualifier
No change	<b>P</b> Gastrointestinal Tract <b>Q</b> Respiratory Tract <b>R</b> Genitourinary Tract	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic <b>7</b> Via Natural or Artificial Opening <b>8</b> Via Natural or Artificial Opening Endoscopic <b>X</b> External	<b>1</b> Radioactive Element <b>3</b> Infusion Device <b>Y</b> Other Device	<b>Z</b> No Qualifier

# 5A0

	<i>Section</i>	<b>5</b>	Extracorporeal or Systemic Assistance and Performance	
No change	<i>Body System</i>	<b>A</b>	Physiological Systems	
	<i>Operation</i>	<b>0</b>	Assistance: Taking over a portion of a physiological function by extracorporeal means	
Heading	<i>Body System</i>	<i>Duration</i>	<i>Function</i>	<i>Qualifier</i>
No change	<b>2</b> Cardiac	<b>1</b> Intermittent	<b>1</b> Output	<b>0</b> Balloon Pump <b>5</b> Pulsatile Compression <b>6</b> Other Pump <b>D</b> Impeller Pump
No change	<b>2</b> Cardiac	<b>2</b> Continuous	<b>1</b> Output	<b>0</b> Balloon Pump <b>5</b> Pulsatile Compression <b>6</b> Other Pump <b>D</b> Impeller Pump
No change	<b>2</b> Cardiac	<b>2</b> Continuous	<b>2</b> Oxygenation	<b>C</b> Supersaturated
No change	<b>5</b> Circulatory	<b>1</b> Intermittent <b>2</b> Continuous	<b>2</b> Oxygenation	<b>1</b> Hyperbaric
No change	<b>9</b> Respiratory	<b>2</b> Continuous	<b>0</b> Filtration	<b>Z</b> No Qualifier
No change	<b>9</b> Respiratory	<b>3</b> Less than 24 Consecutive Hours <b>4</b> 24-96 Consecutive Hours <b>5</b> Greater than 96 Consecutive Hours	<b>5</b> Ventilation	<b>7</b> Continuous Positive Airway Pressure <b>8</b> Intermittent Positive Airway Pressure <b>9</b> Continuous Negative Airway Pressure <b>A</b> High Nasal Flow/Velocity <b>B</b> Intermittent Negative Airway Pressure <b>Z</b> No Qualifier
FY2024	<b>9</b> Respiratory	<b>B</b> Less than 8 Consecutive Hours <b>C</b> 8-24 Consecutive Hours <b>D</b> Greater than 24 Consecutive Hours	<b>5</b> Ventilation	<b>K</b> Intubated Prone Positioning

# 8E0

No change	<i>Section</i>	<b>8</b>	Other Procedures	
No change	<i>Body System</i>	<b>E</b>	Physiological Systems and Anatomical Regions	
No change	<i>Operation</i>	<b>0</b>	Other Procedures: Methodologies which attempt to remediate or cure a disorder or disease	
Heading	<i>Body Region</i>	<i>Approach</i>	<i>Method</i>	<i>Qualifier</i>
FY2024	<b>1</b> Nervous System	<b>X</b> External	<b>Y</b> Other Method	<b>7</b> Examination
No change	<b>2</b> Circulatory System	<b>3</b> Percutaneous <b>X</b> External	<b>D</b> Near Infrared Spectroscopy	<b>Z</b> No Qualifier
No change	<b>9</b> Head and Neck Region	<b>0</b> Open	<b>C</b> Robotic Assisted Procedure	<b>Z</b> No Qualifier
No change	<b>9</b> Head and Neck Region	<b>0</b> Open	<b>E</b> Fluorescence Guided Procedure	<b>M</b> Aminolevulinic Acid <b>Z</b> No Qualifier
No change	<b>9</b> Head and Neck Region	<b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic <b>7</b> Via Natural or Artificial Opening <b>8</b> Via Natural or Artificial Opening Endoscopic	<b>C</b> Robotic Assisted Procedure <b>E</b> Fluorescence Guided Procedure	<b>Z</b> No Qualifier
No change	<b>9</b> Head and Neck Region	<b>X</b> External	<b>B</b> Computer Assisted Procedure	<b>F</b> With Fluoroscopy <b>G</b> With Computerized Tomography <b>H</b> With Magnetic Resonance Imaging <b>Z</b> No Qualifier
No change	<b>9</b> Head and Neck Region	<b>X</b> External	<b>C</b> Robotic Assisted Procedure	<b>Z</b> No Qualifier
No change	<b>9</b> Head and Neck Region	<b>X</b> External	<b>Y</b> Other Method	<b>8</b> Suture Removal
No change	<b>H</b> Integumentary System and Breast	<b>3</b> Percutaneous	<b>0</b> Acupuncture	<b>0</b> Anesthesia <b>Z</b> No Qualifier
No change	<b>H</b> Integumentary System and Breast	<b>X</b> External	<b>6</b> Collection	<b>2</b> Breast Milk
No change	<b>H</b> Integumentary System and Breast	<b>X</b> External	<b>Y</b> Other Method	<b>9</b> Piercing
No change	<b>K</b> Musculoskeletal System	<b>X</b> External	<b>1</b> Therapeutic Massage	<b>Z</b> No Qualifier
No change	<b>K</b> Musculoskeletal System	<b>X</b> External	<b>Y</b> Other Method	<b>7</b> Examination
FY2024	<b>U</b> Female Reproductive System	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic <b>7</b> Via Natural or Artificial Opening <b>8</b> Via Natural or Artificial Opening Endoscopic	<b>E</b> Fluorescence Guided Procedure	<b>N</b> Pafolacianine
FY2024	<b>U</b> Female Reproductive System	<b>X</b> External	<b>Y</b> Other Method	<b>7</b> Examination
No change	<b>V</b> Male Reproductive System	<b>X</b> External	<b>1</b> Therapeutic Massage	<b>C</b> Prostate <b>D</b> Rectum
No change	<b>V</b> Male Reproductive System	<b>X</b> External	<b>6</b> Collection	<b>3</b> Sperm

FY2024	<b>W</b> Trunk Region	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic <b>7</b> Via Natural or Artificial Opening <b>8</b> Via Natural or Artificial Opening Endoscopic	<b>C</b> Robotic Assisted Procedure	<b>Z</b> No Qualifier
FY2024	<b>W</b> Trunk Region	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic <b>7</b> Via Natural or Artificial Opening <b>8</b> Via Natural or Artificial Opening Endoscopic	<b>E</b> Fluorescence Guided Procedure	<b>N</b> Pafolacianine <b>Z</b> No Qualifier
No change	<b>W</b> Trunk Region	<b>X</b> External	<b>B</b> Computer Assisted Procedure	<b>F</b> With Fluoroscopy <b>G</b> With Computerized Tomography <b>H</b> With Magnetic Resonance Imaging <b>Z</b> No Qualifier
No change	<b>W</b> Trunk Region	<b>X</b> External	<b>C</b> Robotic Assisted Procedure	<b>Z</b> No Qualifier
No change	<b>W</b> Trunk Region	<b>X</b> External	<b>Y</b> Other Method	<b>8</b> Suture Removal
No change	<b>X</b> Upper Extremity <b>Y</b> Lower Extremity	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>C</b> Robotic Assisted Procedure <b>E</b> Fluorescence Guided Procedure	<b>Z</b> No Qualifier
No change	<b>X</b> Upper Extremity <b>Y</b> Lower Extremity	<b>X</b> External	<b>B</b> Computer Assisted Procedure	<b>F</b> With Fluoroscopy <b>G</b> With Computerized Tomography <b>H</b> With Magnetic Resonance Imaging <b>Z</b> No Qualifier
No change	<b>X</b> Upper Extremity <b>Y</b> Lower Extremity	<b>X</b> External	<b>C</b> Robotic Assisted Procedure	<b>Z</b> No Qualifier
No change	<b>X</b> Upper Extremity <b>Y</b> Lower Extremity	<b>X</b> External	<b>Y</b> Other Method	<b>8</b> Suture Removal
No change	<b>Z</b> None	<b>X</b> External	<b>Y</b> Other Method	<b>1</b> In Vitro Fertilization <b>4</b> Yoga Therapy <b>5</b> Meditation <b>6</b> Isolation

# X05

FY2024	<i>Section</i>	<b>X</b> New Technology		
	<i>Body System</i>	<b>0</b> Nervous System		
	<i>Operation</i>	<b>5</b> Destruction: Physical eradication of all or a portion of a body part by the direct use of energy, force, or a destructive agent		
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
FY2024	<b>1</b> Renal Sympathetic Nerve(s)	<b>3</b> Percutaneous	<b>2</b> Ultrasound Ablation	<b>9</b> New Technology Group 9



## X2H

FY2024	<i>Section</i>	<b>X</b>	New Technology		
	<i>Body System</i>	<b>2</b>	Cardiovascular System		
	<i>Operation</i>	<b>H</b>	Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part		
Heading	<i>Body Part</i>		<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
FY2024	<b>0</b> Inferior Vena Cava <b>1</b> Superior Vena Cava		<b>3</b> Percutaneous	<b>R</b> Intraluminal Device, Bioprosthetic Valve	<b>9</b> New Technology Group 9
FY2024	<b>2</b> Femoral Vein, Right <b>3</b> Femoral Vein, Left		<b>0</b> Open	<b>R</b> Intraluminal Device, Bioprosthetic Valve	<b>9</b> New Technology Group 9
FY2024	<b>6</b> Atrium, Right <b>K</b> Ventricle, Right		<b>3</b> Percutaneous	<b>V</b> Intracardiac Pacemaker, Dual-Chamber	<b>9</b> New Technology Group 9
FY2024	<b>L</b> Axillary Artery, Right <b>M</b> Axillary Artery, Left <b>X</b> Thoracic Aorta, Ascending		<b>0</b> Open	<b>F</b> Conduit to Short-term External Heart Assist System	<b>9</b> New Technology Group 9

## X2K

No change	<b>Section X</b> New Technology <b>Body System 2</b> Cardiovascular System <b>Operation K</b> Bypass: Altering the route of passage of the contents of a tubular body part			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	<b>B</b> Radial Artery, Right <b>C</b> Radial Artery, Left	<b>3</b> Percutaneous	<b>1</b> Thermal Resistance Energy	<b>7</b> New Technology Group 7
FY2024	<b>H</b> Femoral Artery, Right <b>J</b> Femoral Artery, Left	<b>3</b> Percutaneous	<b>D</b> Conduit through Femoral Vein to Superficial Femoral Artery <b>E</b> Conduit through Femoral Vein to Popliteal Artery	<b>9</b> New Technology Group 9

# X2U

FY2024	<i>Section</i> <b>X</b> New Technology <i>Body System</i> <b>2</b> Cardiovascular System <i>Operation</i> <b>U</b> Supplement: Putting in or on biological or synthetic material that physically reinforces and/or augments the function of a portion of a body part			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
FY2024	<b>4</b> Coronary Artery/Arteries	<b>0</b> Open	<b>7</b> Vein Graft Extraluminal Support Device(s)	<b>9</b> New Technology Group 9
FY2024	<b>Q</b> Upper Extremity Vein, Right <b>R</b> Upper Extremity Vein, Left	<b>0</b> Open	<b>P</b> Synthetic Substitute, Extraluminal Support Device	<b>9</b> New Technology Group 9

# XNH

No change	<i>Section</i>	<b>X</b>	New Technology		
	<i>Body System</i>	<b>N</b>	Bones		
	<i>Operation</i>	<b>H</b>	Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part		
Heading	<i>Body Part</i>		<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	<b>6</b> Pelvic Bone, Right <b>7</b> Pelvic Bone, Left		<b>0</b> Open <b>3</b> Percutaneous	<b>5</b> Internal Fixation Device with Tulip Connector	<b>8</b> New Technology Group 8
FY2024	<b>G</b> Tibia, Right <b>H</b> Tibia, Left		<b>0</b> Open	<b>F</b> Tibial Extension with Motion Sensors	<b>9</b> New Technology Group 9

# XNR

FY2024	<i>Section</i>	<b>X</b>	New Technology	
	<i>Body System</i>	<b>N</b>	Bones	
	<i>Operation</i>	<b>R</b>	Replacement: Putting in or on biological or synthetic material that physically takes the place and/or function of all or a portion of a body part	
Heading	<i>Body Part</i>		<i>Approach</i>	<i>Device / Substance / Technology</i>
FY2024	<b>8</b> Skull		<b>0</b> Open	<b>D</b> Synthetic Substitute, Ultrasound Penetrable
FY2024	<b>L</b> Tarsal, Right <b>M</b> Tarsal, Left		<b>0</b> Open	<b>9</b> Synthetic Substitute, Talar Prosthesis
				<b>9</b> New Technology Group 9
				<b>9</b> New Technology Group 9

# XRG

No change	<b>Section</b> <b>X</b> New Technology <b>Body System</b> <b>R</b> Joints <b>Operation</b> <b>G</b> Fusion: Joining together portions of an articular body part rendering the articular body part immobile																				
Heading	<table border="1"> <thead> <tr> <th><i>Body Part</i></th> <th><i>Approach</i></th> <th><i>Device / Substance / Technology</i></th> <th><i>Qualifier</i></th> </tr> </thead> <tbody> <tr> <td> <b>A</b> Thoracolumbar Vertebral Joint  <b>B</b> Lumbar Vertebral Joint  <b>C</b> Lumbar Vertebral Joints, 2 or more  <b>D</b> Lumbosacral Joint         </td> <td> <b>0</b> Open  <b>3</b> Percutaneous  <b>4</b> Percutaneous Endoscopic         </td> <td> <b>R</b> Interbody Fusion Device, Customizable         </td> <td> <b>7</b> New Technology Group 7         </td> </tr> <tr> <td> <b>A</b> Thoracolumbar Vertebral Joint  <b>B</b> Lumbar Vertebral Joint  <b>C</b> Lumbar Vertebral Joints, 2 or more  <b>D</b> Lumbosacral Joint         </td> <td> <b>0</b> Open  <b>3</b> Percutaneous  <b>4</b> Percutaneous Endoscopic         </td> <td> <b>R</b> Interbody Fusion Device, Custom-Made Anatomically Designed         </td> <td> <b>7</b> New Technology Group 7         </td> </tr> <tr> <td> <b>E</b> Sacroiliac Joint, Right  <b>F</b> Sacroiliac Joint, Left         </td> <td> <b>0</b> Open  <b>3</b> Percutaneous         </td> <td> <b>5</b> Internal Fixation Device with Tulip Connector         </td> <td> <b>8</b> New Technology Group 8         </td> </tr> <tr> <td> <b>J</b> Ankle Joint, Right  <b>K</b> Ankle Joint, Left  <b>L</b> Tarsal Joint, Right  <b>M</b> Tarsal Joint, Left         </td> <td> <b>0</b> Open         </td> <td> <b>B</b> Internal Fixation Device, Open-truss Design         </td> <td> <b>9</b> New Technology Group 9         </td> </tr> </tbody> </table>	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>	<b>A</b> Thoracolumbar Vertebral Joint <b>B</b> Lumbar Vertebral Joint <b>C</b> Lumbar Vertebral Joints, 2 or more <b>D</b> Lumbosacral Joint	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>R</b> Interbody Fusion Device, Customizable	<b>7</b> New Technology Group 7	<b>A</b> Thoracolumbar Vertebral Joint <b>B</b> Lumbar Vertebral Joint <b>C</b> Lumbar Vertebral Joints, 2 or more <b>D</b> Lumbosacral Joint	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>R</b> Interbody Fusion Device, Custom-Made Anatomically Designed	<b>7</b> New Technology Group 7	<b>E</b> Sacroiliac Joint, Right <b>F</b> Sacroiliac Joint, Left	<b>0</b> Open <b>3</b> Percutaneous	<b>5</b> Internal Fixation Device with Tulip Connector	<b>8</b> New Technology Group 8	<b>J</b> Ankle Joint, Right <b>K</b> Ankle Joint, Left <b>L</b> Tarsal Joint, Right <b>M</b> Tarsal Joint, Left	<b>0</b> Open	<b>B</b> Internal Fixation Device, Open-truss Design	<b>9</b> New Technology Group 9
<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>																		
<b>A</b> Thoracolumbar Vertebral Joint <b>B</b> Lumbar Vertebral Joint <b>C</b> Lumbar Vertebral Joints, 2 or more <b>D</b> Lumbosacral Joint	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>R</b> Interbody Fusion Device, Customizable	<b>7</b> New Technology Group 7																		
<b>A</b> Thoracolumbar Vertebral Joint <b>B</b> Lumbar Vertebral Joint <b>C</b> Lumbar Vertebral Joints, 2 or more <b>D</b> Lumbosacral Joint	<b>0</b> Open <b>3</b> Percutaneous <b>4</b> Percutaneous Endoscopic	<b>R</b> Interbody Fusion Device, Custom-Made Anatomically Designed	<b>7</b> New Technology Group 7																		
<b>E</b> Sacroiliac Joint, Right <b>F</b> Sacroiliac Joint, Left	<b>0</b> Open <b>3</b> Percutaneous	<b>5</b> Internal Fixation Device with Tulip Connector	<b>8</b> New Technology Group 8																		
<b>J</b> Ankle Joint, Right <b>K</b> Ankle Joint, Left <b>L</b> Tarsal Joint, Right <b>M</b> Tarsal Joint, Left	<b>0</b> Open	<b>B</b> Internal Fixation Device, Open-truss Design	<b>9</b> New Technology Group 9																		
Revise from																					
Revise to																					
No change																					
FY2024																					

# XV5

FY2023

<i>Section</i>	<b>X</b>	New Technology
<i>Body System</i>	<b>V</b>	Male Reproductive System
<i>Operation</i>	<b>5</b>	Destruction: Physical eradication of all or a portion of a body part by the direct use of energy, force, or a destructive agent

# XW0

No change	<i>Section</i>	<b>X</b> New Technology		
	<i>Body System</i>	<b>W</b> Anatomical Regions		
	<i>Operation</i>	<b>0</b> Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products		
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
Revise from	<b>0</b> Skin	<b>X</b> External	<b>2</b> Bromelain-enriched Proteolytic Enzyme	<b>7</b> New Technology Group 7
Revise to	<b>0</b> Skin	<b>X</b> External	<b>2</b> Anacaulase-bcdb	<b>7</b> New Technology Group 7
No change	<b>1</b> Subcutaneous Tissue	<b>3</b> Percutaneous	<b>1</b> Daratumumab and Hyaluronidase-fihj <b>4</b> Teclistamab Antineoplastic	<b>8</b> New Technology Group 8
No change	<b>1</b> Subcutaneous Tissue	<b>3</b> Percutaneous	<b>9</b> Satralizumab-mwge	<b>7</b> New Technology Group 7
No change	<b>1</b> Subcutaneous Tissue	<b>3</b> Percutaneous	<b>F</b> Other New Technology Therapeutic Substance	<b>5</b> New Technology Group 5
FY2024	<b>1</b> Subcutaneous Tissue	<b>3</b> Percutaneous	<b>G</b> REGN-COV2 Monoclonal Antibody <b>H</b> Other New Technology Monoclonal Antibody <b>K</b> Leronlimab Monoclonal Antibody	<b>6</b> New Technology Group 6
FY2024	<b>1</b> Subcutaneous Tissue	<b>3</b> Percutaneous	<b>L</b> Elranatamab Antineoplastic	<b>9</b> New Technology Group 9
FY2024	<b>1</b> Subcutaneous Tissue	<b>3</b> Percutaneous	<b>S</b> COVID-19 Vaccine Dose 1	<b>6</b> New Technology Group 6
FY2024	<b>1</b> Subcutaneous Tissue	<b>3</b> Percutaneous	<b>S</b> Epcoritamab Monoclonal Antibody	<b>9</b> New Technology Group 9
FY2024	<b>1</b> Subcutaneous Tissue	<b>3</b> Percutaneous	<b>T</b> COVID-19 Vaccine Dose 2 <b>U</b> COVID-19 Vaccine	<b>6</b> New Technology Group 6
No change	<b>1</b> Subcutaneous Tissue	<b>3</b> Percutaneous	<b>V</b> COVID-19 Vaccine Dose 3	<b>7</b> New Technology Group 7
No change	<b>1</b> Subcutaneous Tissue	<b>3</b> Percutaneous	<b>W</b> Caplacizumab	<b>5</b> New Technology Group 5
No change	<b>1</b> Subcutaneous Tissue	<b>3</b> Percutaneous	<b>W</b> COVID-19 Vaccine Booster	<b>7</b> New Technology Group 7
Revise from	<b>1</b> Subcutaneous Tissue	<b>X</b> External	<b>2</b> Bromelain-enriched Proteolytic Enzyme	<b>7</b> New Technology Group 7
Revise to	<b>1</b> Subcutaneous Tissue	<b>X</b> External	<b>2</b> Anacaulase-bcdb	<b>7</b> New Technology Group 7
No change	<b>2</b> Muscle	<b>0</b> Open	<b>D</b> Engineered Allogeneic Thymus Tissue	<b>8</b> New Technology Group 8
No change	<b>2</b> Muscle	<b>3</b> Percutaneous	<b>S</b> COVID-19 Vaccine Dose 1 <b>T</b> COVID-19 Vaccine Dose 2 <b>U</b> COVID-19 Vaccine	<b>6</b> New Technology Group 6
No change	<b>2</b> Muscle	<b>3</b> Percutaneous	<b>V</b> COVID-19 Vaccine Dose 3 <b>W</b> COVID-19 Vaccine Booster <b>X</b> Tixagevimab and Cilgavimab Monoclonal Antibody <b>Y</b> Other New Technology Monoclonal Antibody	<b>7</b> New Technology Group 7
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>0</b> Brexanolone	<b>6</b> New Technology Group 6
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>0</b> Spesolimab Monoclonal Antibody	<b>8</b> New Technology Group 8



No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>2</b> Nerinitide <b>3</b> Durvalumab Antineoplastic	<b>6</b> New Technology Group 6
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>5</b> Narsoplimab Monoclonal Antibody	<b>7</b> New Technology Group 7
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>5</b> Mosunetuzumab Antineoplastic	<b>8</b> New Technology Group 8
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>6</b> Lefamulin Anti-infective	<b>6</b> New Technology Group 6
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>6</b> Terlipressin	<b>7</b> New Technology Group 7
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>6</b> Afamitresgene Autoleucl Immunotherapy	<b>8</b> New Technology Group 8
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>7</b> Coagulation Factor Xa, Inactivated	<b>2</b> New Technology Group 2
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>7</b> Trilaciclib	<b>7</b> New Technology Group 7
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>7</b> Tabelecleucl Immunotherapy	<b>8</b> New Technology Group 8
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>8</b> Lurbinedectin	<b>7</b> New Technology Group 7
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>8</b> Treosulfan	<b>8</b> New Technology Group 8
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>9</b> Ceftolozane/Tazobactam Anti-infective	<b>6</b> New Technology Group 6
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>9</b> Inebilizumab-cdon	<b>8</b> New Technology Group 8
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>A</b> Cefiderocol Anti-infective	<b>6</b> New Technology Group 6
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>A</b> Ciltacabtagene Autoleucl	<b>7</b> New Technology Group 7
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>B</b> Cytarabine and Daunorubicin Liposome Antineoplastic	<b>3</b> New Technology Group 3
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>B</b> Omadacycline Anti-infective	<b>6</b> New Technology Group 6
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>B</b> Amivantamab Monoclonal Antibody	<b>7</b> New Technology Group 7
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>C</b> Eculizumab	<b>6</b> New Technology Group 6
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>C</b> Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	<b>7</b> New Technology Group 7
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>D</b> Atezolizumab Antineoplastic	<b>6</b> New Technology Group 6
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>E</b> Remdesivir Anti-infective	<b>5</b> New Technology Group 5
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>E</b> Etesevimab Monoclonal Antibody	<b>6</b> New Technology Group 6
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>F</b> Other New Technology Therapeutic Substance	<b>3</b> New Technology Group 3
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>F</b> Other New Technology Therapeutic Substance	<b>5</b> New Technology Group 5
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>F</b> Bamlanivimab Monoclonal Antibody	<b>6</b> New Technology Group 6
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>G</b> Sarilumab	<b>5</b> New Technology Group 5
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>G</b> REGN-COV2 Monoclonal Antibody	<b>6</b> New Technology Group 6
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>G</b> Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	<b>7</b> New Technology Group 7
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>H</b> Tocilizumab	<b>5</b> New Technology Group 5
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>H</b> Other New Technology Monoclonal Antibody	<b>6</b> New Technology Group 6
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>H</b> Axicabtagene Ciloleucl Immunotherapy <b>J</b> Tisagenlecleucl Immunotherapy	<b>7</b> New Technology Group 7
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>K</b> Fosfomycin Anti-infective	<b>5</b> New Technology Group 5

No change	3 Peripheral Vein	3 Percutaneous	K Idecabtagene Vicleucel Immunotherapy	7 New Technology Group 7
FY2024	3 Peripheral Vein	3 Percutaneous	K Sulbactam-Durlobactam	9 New Technology Group 9
No change	3 Peripheral Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	L Lifileucel Immunotherapy M Brexucabtagene Autoleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	N Meropenem-vaborbactam Anti-infective	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	N Lisocabtagene Maraleucel Immunotherapy	7 New Technology Group 7
FY2024	3 Peripheral Vein	3 Percutaneous	P Glofitamab Antineoplastic	9 New Technology Group 9
FY2024	3 Peripheral Vein	3 Percutaneous	Q Tagraxofusp-erzs Antineoplastic	5 New Technology Group 5
FY2024	3 Peripheral Vein	3 Percutaneous	Q Posoleucel R Rezafungin	9 New Technology Group 9
FY2024	3 Peripheral Vein	3 Percutaneous	S Iobenguane I-131 Antineoplastic U Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	0 Brexanolone	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	0 Spesolimab Monoclonal Antibody	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	2 Nerinitide 3 Durvalumab Antineoplastic	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	5 Narsoplimab Monoclonal Antibody	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	5 Mosunetuzumab Antineoplastic	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	6 Lefamulin Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	6 Terlipressin	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	6 Afamitresgene Autoleucel Immunotherapy	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated	2 New Technology Group 2
No change	4 Central Vein	3 Percutaneous	7 Trilaciclib	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	7 Tabelecleucel Immunotherapy	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	8 Lurbinectedin	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	8 Treosulfan	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	9 Inebilizumab-cdon	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	A Cefiderocol Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	A Cilta cabtagene Autoleucel	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
No change	4 Central Vein	3 Percutaneous	B Omadacycline Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	B Amivantamab Monoclonal Antibody	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	C Eculizumab	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	7 New Technology Group 7

No change	4 Central Vein	3 Percutaneous	D Atezolizumab Antineoplastic	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	E Etesevimab Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
No change	4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	F Bamlanivimab Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	H Axicabtagene Ciloleucel Immunotherapy J Tisagenlecleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	K Fosfomycin Anti-infective	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	K Idecabtagene Vicleucel Immunotherapy	7 New Technology Group 7
FY2024	4 Central Vein	3 Percutaneous	K Sulbactam-Durlobactam	9 New Technology Group 9
No change	4 Central Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	L Lifileucel Immunotherapy M Brexucabtagene Autoleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	N Meropenem-vaborbactam Anti-infective	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	N Lisocabtagene Maraleucel Immunotherapy	7 New Technology Group 7
FY2024	4 Central Vein	3 Percutaneous	P Glofitamab Antineoplastic	9 New Technology Group 9
FY2024	4 Central Vein	3 Percutaneous	Q Tagraxofusp-erzs Antineoplastic	5 New Technology Group 5
FY2024	4 Central Vein	3 Percutaneous	Q Posoleucel R Rezafungin	9 New Technology Group 9
FY2024	4 Central Vein	3 Percutaneous	S Iobenguane I-131 Antineoplastic U Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab	5 New Technology Group 5
FY2024	5 Peripheral Artery	3 Percutaneous	T Melphalan Hydrochloride Antineoplastic	9 New Technology Group 9
No change	9 Nose	7 Via Natural or Artificial Opening	M Esketamine Hydrochloride	5 New Technology Group 5
No change	D Mouth and Pharynx	X External	3 Maribavir Anti-infective	8 New Technology Group 8
No change	D Mouth and Pharynx	X External	6 Lefamulin Anti-infective	6 New Technology Group 6
No change	D Mouth and Pharynx	X External	8 Uridine Triacetate	2 New Technology Group 2
No change	D Mouth and Pharynx	X External	F Other New Technology Therapeutic Substance J Apalutamide Antineoplastic	5 New Technology Group 5
FY2024	D Mouth and Pharynx	X External	J Quizartinib Antineoplastic	9 New Technology Group 9

No change	<b>D</b> Mouth and Pharynx	<b>X</b> External	<b>K</b> Sabizabulin	<b>8</b> New Technology Group 8
No change	<b>D</b> Mouth and Pharynx	<b>X</b> External	<b>L</b> Erdafitinib Antineoplastic	<b>5</b> New Technology Group 5
No change	<b>D</b> Mouth and Pharynx	<b>X</b> External	<b>M</b> Baricitinib	<b>6</b> New Technology Group 6
FY2024	<b>D</b> Mouth and Pharynx	<b>X</b> External	<b>N</b> SER-109	<b>9</b> New Technology Group 9
No change	<b>D</b> Mouth and Pharynx	<b>X</b> External	<b>R</b> Venetoclax Antineoplastic	<b>5</b> New Technology Group 5
No change	<b>D</b> Mouth and Pharynx	<b>X</b> External	<b>R</b> Fostamatinib	<b>7</b> New Technology Group 7
No change	<b>D</b> Mouth and Pharynx	<b>X</b> External	<b>T</b> Ruxolitinib <b>V</b> Gilteritinib Antineoplastic	<b>5</b> New Technology Group 5
No change	<b>G</b> Upper GI	<b>7</b> Via Natural or Artificial Opening	<b>3</b> Maribavir Anti-infective <b>K</b> Sabizabulin	<b>8</b> New Technology Group 8
No change	<b>G</b> Upper GI	<b>7</b> Via Natural or Artificial Opening	<b>M</b> Baricitinib	<b>6</b> New Technology Group 6
No change	<b>G</b> Upper GI	<b>7</b> Via Natural or Artificial Opening	<b>R</b> Fostamatinib	<b>7</b> New Technology Group 7
No change	<b>G</b> Upper GI	<b>8</b> Via Natural or Artificial Opening Endoscopic	<b>8</b> Mineral-based Topical Hemostatic Agent	<b>6</b> New Technology Group 6
No change	<b>H</b> Lower GI	<b>7</b> Via Natural or Artificial Opening	<b>3</b> Maribavir Anti-infective <b>K</b> Sabizabulin	<b>8</b> New Technology Group 8
No change	<b>H</b> Lower GI	<b>7</b> Via Natural or Artificial Opening	<b>M</b> Baricitinib	<b>6</b> New Technology Group 6
No change	<b>H</b> Lower GI	<b>7</b> Via Natural or Artificial Opening	<b>R</b> Fostamatinib	<b>7</b> New Technology Group 7
No change	<b>H</b> Lower GI	<b>7</b> Via Natural or Artificial Opening	<b>X</b> Broad Consortium Microbiota-based Live Biotherapeutic Suspension	<b>8</b> New Technology Group 8
No change	<b>H</b> Lower GI	<b>8</b> Via Natural or Artificial Opening Endoscopic	<b>8</b> Mineral-based Topical Hemostatic Agent	<b>6</b> New Technology Group 6
No change	<b>Q</b> Cranial Cavity and Brain	<b>3</b> Percutaneous	<b>1</b> Eladocagene exuparvovec	<b>6</b> New Technology Group 6
No change	<b>V</b> Bones	<b>0</b> Open	<b>P</b> Antibiotic-eluting Bone Void Filler	<b>7</b> New Technology Group 7

# XW1

No change	<b>Section</b> <b>X</b> New Technology <b>Body System</b> <b>W</b> Anatomical Regions <b>Operation</b> <b>1</b> Transfusion: Putting in blood or blood products			
Heading	<b>Body Part</b>	<b>Approach</b>	<b>Device / Substance / Technology</b>	<b>Qualifier</b>
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>2</b> Plasma, Convalescent (Nonautologous)	<b>5</b> New Technology Group 5
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>B</b> Betibeglogene Autotemcel <b>C</b> Omidubicel	<b>8</b> New Technology Group 8
No change	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>D</b> High-Dose Intravenous Immune Globulin <b>E</b> Hyperimmune Globulin	<b>7</b> New Technology Group 7
FY2024	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>F</b> OTL-103 <b>G</b> OTL-200	<b>8</b> New Technology Group 8
FY2024	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>H</b> Lovotibeglogene Autotemcel	<b>9</b> New Technology Group 9
FY2024	<b>3</b> Peripheral Vein	<b>3</b> Percutaneous	<b>J</b> Exagamglogene Autotemcel	<b>8</b> New Technology Group 8
No change	<b>4</b> Central Vein	<b>3</b> Percutaneous	<b>2</b> Plasma, Convalescent (Nonautologous)	<b>5</b> New Technology Group 5
No change	<b>4</b> Central Vein	<b>3</b> Percutaneous	<b>B</b> Betibeglogene Autotemcel <b>C</b> Omidubicel	<b>8</b> New Technology Group 8
No change	<b>4</b> Central Vein	<b>3</b> Percutaneous	<b>D</b> High-Dose Intravenous Immune Globulin <b>E</b> Hyperimmune Globulin	<b>7</b> New Technology Group 7
FY2024	<b>4</b> Central Vein	<b>3</b> Percutaneous	<b>F</b> OTL-103 <b>G</b> OTL-200	<b>8</b> New Technology Group 8
FY2024	<b>4</b> Central Vein	<b>3</b> Percutaneous	<b>H</b> Lovotibeglogene Autotemcel	<b>9</b> New Technology Group 9
FY2024	<b>4</b> Central Vein	<b>3</b> Percutaneous	<b>J</b> Exagamglogene Autotemcel	<b>8</b> New Technology Group 8

# XX2

FY2024	<i>Section</i> <b>X</b> New Technology <i>Body System</i> <b>X</b> Physiological Systems <i>Operation</i> <b>2</b> Monitoring: Determining the level of a physiological or physical function repetitively over a period of time			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
FY2024	<b>0</b> Central Nervous	<b>X</b> External	<b>8</b> Brain Electrical Activity, Computer-aided Detection and Notification	<b>9</b> New Technology Group 9
FY2024	<b>F</b> Musculoskeletal	<b>3</b> Percutaneous	<b>W</b> Muscle Compartment Pressure, Micro-Electro-Mechanical System	<b>9</b> New Technology Group 9

# XXE

No change	<i>Section</i>	<b>X</b>	New Technology	
	<i>Body System</i>	<b>X</b>	Physiological Systems	
	<i>Operation</i>	<b>E</b>	Measurement: Determining the level of a physiological or physical function at a point in time	
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	<b>0</b> Central Nervous	<b>X</b> External	<b>0</b> Intracranial Vascular Activity, Computer-aided Assessment	<b>7</b> New Technology Group 7
No change	<b>0</b> Central Nervous	<b>X</b> External	<b>4</b> Brain Electrical Activity, Computer-aided Semiologic Analysis	<b>8</b> New Technology Group 8
FY2024	<b>2</b> Cardiac	<b>X</b> External	<b>1</b> Output, Computer-aided Assessment	<b>9</b> New Technology Group 9
No change	<b>3</b> Arterial	<b>X</b> External	<b>2</b> Pulmonary Artery Flow, Computer-aided Triage and Notification	<b>7</b> New Technology Group 7
No change	<b>3</b> Arterial	<b>X</b> External	<b>5</b> Coronary Artery Flow, Quantitative Flow Ratio Analysis <b>6</b> Coronary Artery Flow, Computer-aided Valve Modeling and Notification	<b>8</b> New Technology Group 8
No change	<b>5</b> Circulatory	<b>X</b> External	<b>3</b> Infection, Whole Blood Reverse Transcription and Quantitative Real-time Polymerase Chain Reaction	<b>8</b> New Technology Group 8
No change	<b>5</b> Circulatory	<b>X</b> External	<b>M</b> Infection, Whole Blood Nucleic Acid-base Microbial Detection	<b>5</b> New Technology Group 5
No change	<b>5</b> Circulatory	<b>X</b> External	<b>N</b> Infection, Positive Blood Culture Fluorescence Hybridization for Organism Identification, Concentration and Susceptibility	<b>6</b> New Technology Group 6
No change	<b>5</b> Circulatory	<b>X</b> External	<b>R</b> Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure <b>T</b> Intracranial Arterial Flow, Whole Blood mRNA <b>V</b> Infection, Serum/Plasma Nanoparticle Fluorescence SARS-CoV-2 Antibody Detection	<b>7</b> New Technology Group 7
FY2024	<b>5</b> Circulatory	<b>X</b> External	<b>Y</b> Infection, Other Positive Blood/Isolated Colonies Bimodal Phenotypic Susceptibility Technology	<b>9</b> New Technology Group 9
No change	<b>9</b> Nose	<b>7</b> Via Natural or Artificial Opening	<b>U</b> Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction	<b>7</b> New Technology Group 7
No change	<b>B</b> Respiratory	<b>X</b> External	<b>Q</b> Infection, Lower Respiratory Fluid Nucleic Acid-base Microbial Detection	<b>6</b> New Technology Group 6